Press release
Demand for Hospital-Treated Gram-Negative Infections Market from Key End-use Sectors to Surge in the Near Future
Gram-negative bacteria are non-pathogenic in person with the normal immune system. However, in person with a weak immune system having gram negative bacteria can behave as significant pathogens. The ability to prevent the effect of such micro-organisms is significantly hampered by the resistance of antimicrobials. The above is the reason for the introduction, and continuous research on combination antibiotics and physicians are now concentrating on selecting an appropriate empiric antibiotic therapy for treating the nosocomial infection. Furthermore, the multidrug-resistant gram-negative organisms have come out to be an accountable threat to the patients and are responsible for rising in mortality rate from 30 to 70% in infections category. Inappropriate use of broad-spectrum antibiotics abundantly and regularly is highly contributing to the emergence of MDRGNs. The advent and propagation of these highly resistant gram-negative organisms are a matter of concern due to the limited number of currently available antimicrobial agents or in the pipeline drug combat these organisms.Gram-negative bacteria are pathogens and carriers of many diseases that affected the flora found living naturally in the human gut. There are numerous reasons involved where such bacteria become resistant to the antibiotics from, which they have been sensitive to in the past. As a result, the traditional antibiotics are no longer effective in treating the diseases and infections caused due to these microorganisms.
Rising prevalence of various rare disease globally is expected to support the criteria of hospital-treated gram-negative infections market. There has been rising need for newer drugs for getting the appropriate effect on the micro-organisms. The increasing number of strains of the bacteria and growing resistance towards the previously existing pathogens are expected to favor the market for drugs used hospital-treated gram-negative infections. The world is running out of drugs for infections caused due to gram-negative bacteria. However, companies are laying efforts in drug discoveries by spending more and more in research and development. Furthermore, among all of the bacterial resistance problems, gram-negative pathogens are particularly troublesome and a reason for major worry in physician community as they are getting resistant to maximum currently available drugs. The most common gram-negative infections include the pathogens such as Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter. Major challenges are rising for the treatment of patient suffering from pan-resistant or nearly pan-resistant gram-negative microorganisms.
Request for Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/12910
The global market for hospital-treated gram-negative Infections market is segmented on the basis of drug class, indication, application, and distribution channel:
• Segmentation by Therapy
o Cephalosporin, Aminoglycoside
o Ampicillin/sulbactam, Carbapenem, Colistin or Rifampin
o Aminoglycoside, Carbapenem, Colistin, Fosfomycin, Rifampin, or Tigecycline
o Ceftolozane/Tazobactam
o Ceftazidime/Avibactam
o Others
• Segmentation by Pathogen type
o Klebsiella
o Acinetobacter
o Coli
o cepacia
o Pseudomonas
o Serratia
o Enterobacter
o Others
Powerful and frequent administration of antibiotics is becoming a standard-of-care treatment for gram-negative infections, specifically for those diseases acquired in healthcare facilities such as hospitals, nursing homes and long-term care facilities. As a result of frequently acquired infections, the rise in antimicrobial resistance rates has forced an immediate need to introduce novel antibiotic therapies with activity against multidrug-resistant gram-negative pathogens. As a result, various commercial opportunities falls particularly in the healthcare facilities, for latest brands defining clinical efficacy in patients with resistant infections, and precisely in those associated with high mortality rate. Nevertheless, the hospitals need to take perfect steps to prevent such infections such as basic cleanliness acquired by the patients in the hospitals and other medical facilities, use of disinfected instruments for treatment and making the people aware of the consequences of overusing antibiotics.
Although, the reasons mentioned above may further act as an impediment for the market for the drugs used in hospital-treated gram-negative infections somehow is expected to maintain the traction for currently existing antibiotics. Shown improvements over presently available gram negative infection agents are expected to be key during reimbursement and pricing negotiations among the government and the pharmaceutical companies. The provision of positioning gram-negative infections antibiotics in the hospital formulary is also expected to be a key driver of market access in the hospital-treated gram-negative infections drugs market. Furthermore, hospital-treated GNI market is being dominated by generics available in the market as most of the infections can be treated effectively with older agents present in the generic form, which in turn is expected to impede the hospital-treated gram-negative infections drugs market. Novel and recently approved antibiotics are typically reserved for future prospected in the case where the older antibiotics are strongly resisting by gram-negative bacteria.
Need Customization on this Report? Ask here @ https://www.persistencemarketresearch.com/request-customization/12910
On the basis of region presence, hospital-treated gram-negative infections market is segmented into five key regions: North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. Presently, North America dominates the global market for hospital-treated gram-negative infections due to existing large number of facilities for research and development. However, growth in Asia-Pacific region is significant in terms of CAGR over the forecast period due to rising in resistance due to improper scheduled of antibiotics administration. The U.S. Hospital-treated gram-negative infections market is expected to dominate in terms of market share with significant share among all the regions.
Some player exists in this group that are Merck, Pfizer, AstraZeneca, Abbott, Lupin Pharmaceuticals Ltd., Istituto lusofarmaco d'italia spa, Adelco S.A, Zhejiang yuntao biotechnology co., Ltd, Alcon Laboratories, Inc.
Contact Us:
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com
About us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Demand for Hospital-Treated Gram-Negative Infections Market from Key End-use Sectors to Surge in the Near Future here
News-ID: 2703129 • Views: …
More Releases from Persistence Market Research

Plastic Liner Market to Reach US$ 6.67 Bn by 2030, Expanding at 4.7% CAGR - Pers …
➤ Overview of the Market
The global plastic liner market has gained steady traction across multiple industries due to its cost-effectiveness, versatility, and protective characteristics. Plastic liners are widely used in agriculture, mining, construction, waste management, and packaging industries, where they serve as an essential barrier to prevent leakage, contamination, and material loss. These liners are manufactured using materials such as polyethylene (PE), polypropylene (PP), and PVC, offering superior resistance to…

Returnable Plastic Crate Market to Reach US$ 2,665.1 Million by 2030 Fueled by S …
➤ Overview of the Market
The global returnable plastic crate market is gaining momentum as industries seek cost-effective and sustainable packaging solutions. These crates are widely used for transporting and storing perishable goods, beverages, pharmaceuticals, and industrial products due to their durability, stackability, and reusability. The shift from single-use packaging to eco-friendly alternatives has accelerated the adoption of returnable plastic crates across sectors. The market, valued at US$ 1,820.0 million in…

US Thermal Power Market Expected to Reach US$ 251.9 Mn by 2031 with 2.4% CAGR Gr …
➤Overview of the Market
The US thermal power market plays a crucial role in the nation's energy mix, serving as a stable and reliable source of electricity despite the rise of renewables. Thermal power plants in the US rely primarily on coal, natural gas, and oil to generate electricity, with natural gas emerging as the dominant fuel source due to its affordability, efficiency, and lower carbon footprint compared to coal. According…

Europe Medical Plastic Market to Reach US$ 17 Bn by 2032 Driven by Rising Health …
➤Overview of the Market
The Europe medical plastic market is undergoing robust growth, fueled by increasing demand for lightweight, durable, and cost-effective materials in the healthcare sector. Medical plastics are widely used in devices, surgical instruments, diagnostic tools, implants, and packaging due to their high biocompatibility, versatility, and resistance to sterilization methods. With healthcare systems across Europe investing heavily in modernization and patient safety, the adoption of medical-grade plastics has gained…
More Releases for Infections
Campylobacter Infections Market Outlook Report 2032 | Campylobacter Infections M …
DelveInsight's "Campylobacter Infections Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Campylobacter Infections, historical and forecasted epidemiology as well as the Campylobacter Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Campylobacter Infections market report provides current treatment practices, emerging drugs, Campylobacter Infections market share of the individual therapies, and current and forecasted Campylobacter Infections market size…
Point of Care Molecular Diagnostics Market Size Worth $5,665.3 Million By 2028: …
Global “Point of Care Molecular Diagnostics Market” 2021 –2028 Research Report is an extensive Industry report contains an introduction on new trends that can guide the businesses performing in the Life Science industry to recognize the market and make the strategies for their industry growth accordingly. The Point of Care Molecular Diagnostics research report study the market scope, Industry segment, key drivers for development, major segments, and SWOT Analysis.
Global PoC…
Amoxicillin Drugs Market Expansion Projected to Gain an Uptick During 2018 to 20 …
Amoxicillin Drugs: Market Insights
Amoxicillin drugs is a form of generic drugs of Amoxil branded drug commonly used in the treatment of bacterial infections. The Amoxicillin drugs fall under the drug class of β-lactam antibiotic. The increasing number of bacterial infections around the world, especially, in the developing and low-income countries is one of the reasons for the growing demand for Amoxicillin drugs and hence, boosting the growth of Amoxicillin drugs…
Burkholderia Infections Market
Burkholderia infections are caused by Burkholderia cepacia. It is a gram negative bacillus found in aquatic environment. It is a low virulent bacteria and is a frequent colonizer of fluids used in the hospitals such as IV fluid, irrigation solution etc. B. cepacia can cause health problems to some people such as patients suffering from weakened immune system or chronic lung diseases. Burkholderia infection symptom can vary widely in people,…
Burkholderia Infections Market
Burkholderia infections are caused by Burkholderia cepacia. It is a gram negative bacillus found in aquatic environment. It is a low virulent bacteria and is a frequent colonizer of fluids used in the hospitals such as IV fluid, irrigation solution etc. B. cepacia can cause health problems to some people such as patients suffering from weakened immune system or chronic lung diseases. Burkholderia infection symptom can vary widely in people,…
Acinetobacter Infections Treatment Market is Propelled by Increasing Incidence R …
Global Acinetobacter Infections Treatment Market: Overview
Acinetobacter baumannii is a rod shaped gram-negative coccobacillus bacterium. This bacterium is becoming an important cause of hospital derived bacterial infection affecting people with weakened immune system. Acinetobacter infections usually affect organ systems, which have a high content of fluid (e.g. peritoneal fluid, respiratory tract, urinary tract, cerebrospinal fluid etc.) leading to infections related to continuous ambulatory peritoneal dialysis and nocosomial pneumonia. At present, acinetobacter…